MAA
PTCT icon

Managed Account Advisors’s PTC Therapeutics PTCT Stock Holding History

Managed Account Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		$1K Sell
16
-4
-20% -$233 ﹤0.01% 3000
2015
Q1 		$1K Buy
+20
New +$1.22K ﹤0.01% 2933

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return

Managed Account Advisors's PTCT Position: Q2 2015 in Review

Managed Account Advisors reduced its PTC Therapeutics (PTCT) stake by 20% in Q2 2015, selling an estimated $233 and leaving 16 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #3000.

Managed Account Advisors first reported a position in PTCT in Q1 2015 and has held it in 2 quarters since. 155 funds tracked by Wall St. Rank hold PTCT as of Q2 2015.

  • Managed Account Advisors held 16 shares of PTC Therapeutics worth $1K as of Q2 2015.
  • Managed Account Advisors sold 4 PTC Therapeutics shares in Q2 2015, an estimated $233.
  • PTC Therapeutics made up ﹤0.01% of Managed Account Advisors's portfolio in Q2 2015, its #3000 holding.
  • Managed Account Advisors first reported a position in PTC Therapeutics in Q1 2015 and has held it in 2 quarters since.
  • 155 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2015.

Based on Managed Account Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.